Biocon signs licensing and supply pact with Biomm S.A for Semaglutide commercialisation in Brazil
April 22, 2024
Source: drugdu
122
Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes
Biocon announced the signing of an exclusive licensing and supply agreement with Biomm S.A., a specialty pharmaceutical company in Brazil, for the commercialisation of its vertically integrated drug product, Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes.
Under the terms of this agreement, Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market.
Biomm focuses on developing, manufacturing and commercialising complex biotech and biosimilar drug products at their production facility in Nova Lima.
The total addressable market opportunity of Semaglutide in Brazil is approximately $580 million as per the IQVIA MAT Q4 2023.
https://www.expresspharma.in/biocon-signs-licensing-and-supply-pact-with-biomm-s-a-for-semaglutide-commercialisation-in-brazil/
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- $1.4 billion deal highlights the future of Alzheimer’s disease therapy November 5, 2024
- Johnson&Johnson announces latest personnel changes November 5, 2024
- Sonavex announces completion of new round of financing November 5, 2024
- Breaking news, Johnson & Johnson Medical Global Vice President resigns November 5, 2024
- COVID-19 drugs have become a “dark horse” November 5, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
